Online citations, reference lists, and bibliographies.
← Back to Search

Comparative Study On Digestive Lipase Activities On The Self Emulsifying Excipient Labrasol, Medium Chain Glycerides And PEG Esters.

S. Fernandez, V. Jannin, Jean-David Rodier, Nicolas Ritter, B. Mahler, F. Carrière
Published 2007 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Labrasol is a lipid-based self-emulsifying excipient used in the preparation of lipophilic drugs intended for oral delivery. It is mainly composed of PEG esters and glycerides with medium acyl chains, which are potential substrates for digestive lipases. The hydrolysis of Labrasol by porcine pancreatic extracts, human pancreatic juice and several purified digestive lipases was investigated in the present study. Classical human pancreatic lipase (HPL) and porcine pancreatic lipase, which are the main lipases involved in the digestion of dietary triglycerides, showed very low levels of activity on the entire Labrasol excipient as well as on separated fractions of glycerides and PEG esters. On the other hand, gastric lipase, pancreatic lipase-related protein 2 (PLRP2) and carboxyl ester hydrolase (CEH) showed high specific activities on Labrasol. These lipases were found to hydrolyze the main components of Labrasol (PEG esters and monoglycerides) used as individual substrates, whereas these esters were found to be poor substrates for HPL. The lipolytic activity of pancreatic extracts and human pancreatic juice on Labrasol(R) is therefore mainly due to the combined action of CEH and PLRP2. These two pancreatic enzymes, together with gastric lipase, are probably the main enzymes involved in the in vivo lipolysis of Labrasol taken orally.
This paper references
10.1080/00365521.1970.12096592
Tributyrine as a substrate for determination of lipase activity of pancreatic juice and small intestinal content.
C. Erlanson (1970)
10.1016/J.EJPS.2004.08.003
Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols.
J. Christensen (2004)
10.1111/j.2042-7158.1982.tb06204.x
The effect of oils on the lymphatic absorption of DDT
K. Palin (1982)
10.1016/S0378-5173(03)00270-9
Amphiphilic association systems for Amphotericin B delivery.
E. Esposito (2003)
10.1016/S0378-5173(02)00544-6
Enhanced intestinal absorption of vancomycin with Labrasol and D-alpha-tocopheryl PEG 1000 succinate in rats.
Y. V. R. Prasad (2003)
10.1016/S0016-5085(88)80063-5
Gastric lipase: localization in the human stomach.
C. K. Abrams (1988)
10.1016/J.BBAPAP.2004.06.005
Characterization of pancreatic lipase-related protein 2 isolated from human pancreatic juice.
J. De Caro (2004)
10.1016/J.IJPHARM.2003.11.013
In situ intestinal absorption studies on low molecular weight heparin in rats using labrasol as absorption enhancer.
Y. V. Rama Prasad (2004)
10.1111/j.2042-7158.1984.tb04919.x
The effect of different oils on the absorption of probucol in the rat
K. Palin (1984)
10.1016/S0024-3205(01)01375-3
A novel emulsifier, labrasol, enhances gastrointestinal absorption of gentamicin.
Z. Hu (2001)
10.1023/B:PHAM.0000016283.87709.a9
Drug Solubilization Behavior During in Vitro Digestion of Suspension Formulations of Poorly Water-Soluble Drugs in Triglyceride Lipids
A. Kaukonen (2004)
10.1023/B:PHAM.0000036914.22132.cc
Susceptibility to Lipase-Mediated Digestion Reduces the Oral Bioavailability of Danazol After Administration as a Medium-Chain Lipid-Based Microemulsion Formulation
C. H. Porter (2004)
10.1111/J.1432-1033.1991.TB16346.X
Purification and biochemical characterization of dog gastric lipase.
F. Carrière (1991)
10.1002/JPS.10329
Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs.
Greg A Kossena (2003)
10.1080/10611860290022688
Absorption Enhancing Effect of Labrasol on the Intestinal Absorption of Insulin in Rats
S. Eaimtrakarn (2002)
10.1016/S0167-4838(98)00143-5
Pancreatic lipase-related protein 1 (PLRP1) is present in the pancreatic juice of several species.
J. De Caro (1998)
10.1053/GAST.2000.18140
The specific activities of human digestive lipases measured from the in vivo and in vitro lipolysis of test meals.
F. Carrière (2000)
10.1016/0016-5085(93)90908-U
Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans.
F. Carrière (1993)
10.1016/J.IJPHARM.2003.08.008
Evaluation of oral formulations of gentamicin containing labrasol in beagle dogs.
Y. V. Rama Prasad (2003)
10.1016/J.IJPHARM.2004.02.033
Influence of cryogenic grinding on properties of a self-emulsifying formulation.
O. Chambin (2004)
10.1021/BI00176A002
Evidence for a pancreatic lipase subfamily with new kinetic properties.
K. Thirstrup (1994)
10.1016/0167-4781(87)90083-2
Molecular cloning of a human gastric lipase and expression of the enzyme in yeast.
M. Bodmer (1987)
10.1016/S0968-0896(96)00251-9
In vivo and in vitro studies on the stereoselective hydrolysis of tri- and diglycerides by gastric and pancreatic lipases.
F. Carrière (1997)
10.1016/J.BIOPHA.2004.02.001
Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs.
R. N. Gursoy (2004)
10.1023/B:PHAM.0000016282.77887.1f
Drug Solubilization Behavior During in Vitro Digestion of Simple Triglyceride Lipid Solution Formulations
A. Kaukonen (2004)
Hydrolysis of mixed monomolecular films of triglyceride/lecithin by pancreatic lipase.
G. Piéroni (1979)
Rationale for the development of Sandimmune Neoral.
F. Vonderscher (1994)
10.1016/0005-2795(69)90075-0
Purification from porcine pancreas of two molecular species with lipase activity.
R. Verger (1969)
10.1002/3527601910.CH10
Physiology of Gastrointestinal Lipolysis and Therapeutical Use of Lipases and Digestive Lipase Inhibitors
H. Lengsfeld (2005)
10.1074/jbc.274.24.16995
Crystal Structure of Human Gastric Lipase and Model of Lysosomal Acid Lipase, Two Lipolytic Enzymes of Medical Interest*
A. Roussel (1999)
10.1016/0003-2697(76)90527-3
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
M. M. Bradford (1976)
10.1016/S0168-3659(00)00325-4
NMR characterisation and transdermal drug delivery potential of microemulsion systems.
M. Kreilgaard (2000)
10.1007/BF00493829
Immunocytolocalization of human gastric lipase in chief cells of the fundic mucosa
H. Moreau (2004)
Two novel human pancreatic lipase related proteins, hPLRP1 and hPLRP2. Differences in colipase dependence and in lipase activity.
T. Giller (1992)
10.1074/JBC.M109484200
Crystal Structure of the Open Form of Dog Gastric Lipase in Complex with a Phosphonate Inhibitor*
A. Roussel (2002)
10.1021/BI972989G
Structure of bovine pancreatic cholesterol esterase at 1.6 A: novel structural features involved in lipase activation.
J. Chen (1998)
10.1016/S0928-0987(01)00169-5
A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium.
N. H. Zangenberg (2001)
10.1002/JPS.2600671011
Enhancement of bioavailability of a hydrophobic amine antimalarial by formulation with oleic acid in a soft gelatin capsule.
Vittorio Stella (1978)
10.1021/BI049818D
Human pancreatic lipase-related protein 2 is a galactolipase.
B. Sias (2004)
10.1016/0005-2744(80)90049-2
Studies on the substrate specificity of a carboxyl ester hydrolase from human pancreatic juice. I. Action on carboxyl esters, glycerides and phospholipids.
D. Lombardo (1980)
10.1007/BF02535343
Aqueous lipid phases of relevance to intestinal fat digestion and absorption
M. Lindström (2006)
The proteins of human pancreatic external secretion.
O. Guy (1981)
10.3109/10425179809008461
The complete cDNA sequence encoding dog gastric lipase.
S. Vaganay (1998)
10.1016/J.EJPS.2006.04.016
Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system.
C. Pouton (2006)
10.1016/0016-5085(92)91711-C
Dog gastric lipase: stimulation of its secretion in vivo and cytolocalization in mucous pit cells.
F. Carrière (1992)
10.1016/0006-291X(89)91811-1
Cloning of the bovine pancreatic cholesterol esterase/lysophospholipase.
E. Kyger (1989)
10.1006/JMBI.2001.4979
The structure of truncated recombinant human bile salt-stimulated lipase reveals bile salt-independent conformational flexibility at the active-site loop and provides insights into heparin binding.
S. Moore (2001)
10.1111/J.1432-1033.1990.TB19259.X
cDNA cloning of human-milk bile-salt-stimulated lipase and evidence for its identity to pancreatic carboxylic ester hydrolase.
J. Nilsson (1990)



This paper is referenced by
10.1016/j.addr.2018.11.003
Drug supersaturation during formulation digestion, including real-time analytical approaches.
M. Kuentz (2018)
10.1051/OCL.2009.0270
Lauroyl polyoxylglycerides, functionalized coconut oil, enhancing the bioavailability of poorly soluble active substances
V. Jannin (2009)
10.1039/C0AY00104J
Specific assay of carboxyl ester hydrolase using PEG esters as substrate
S. Fernandez (2010)
10.1016/j.jconrel.2008.03.021
Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
A. Dahan (2008)
10.1016/j.jconrel.2014.06.004
Solid lipid excipients - matrix agents for sustained drug delivery.
Y. Rosiaux (2014)
10.1007/s11095-017-2289-x
Lipids in the Stomach – Implications for the Evaluation of Food Effects on Oral Drug Absorption
M. Koziolek (2017)
10.1021/mp300331z
Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.
H. Williams (2012)
10.1039/c6fo00361c
Water-in-oil microemulsions versus emulsions as carriers of hydroxytyrosol: an in vitro gastrointestinal lipolysis study using the pHstat technique.
M. Chatzidaki (2016)
10.1051/OCL.2008.0189
Soixante ans de recherche sur la lipolyse enzymatique des corps gras à Marseille
F. Carrière (2008)
10.1016/j.bbalip.2009.05.002
Continuous measurement of galactolipid hydrolysis by pancreatic lipolytic enzymes using the pH-stat technique and a medium chain monogalactosyl diglyceride as substrate.
S. Amara (2009)
10.1016/j.ejpb.2015.04.027
Chain length affects pancreatic lipase activity and the extent and pH-time profile of triglyceride lipolysis.
Paloma Benito-Gallo (2015)
10.1007/s11095-014-1432-1
Biopharmaceutical Modeling of Drug Supersaturation During Lipid-Based Formulation Digestion Considering an Absorption Sink
Cordula Stillhart (2014)
10.1007/s13228-012-0025-x
Development of the Digestive System—Experimental Challenges and Approaches of Infant Lipid Digestion
E. Abrahamse (2012)
Conception et caractérisation biologique de systèmes lipidiques destinés à une administration par voie orale
Pierre Sae Houer (2010)
10.5451/UNIBAS-005750236
Evaluation of lipid-based formulations of poorly water-soluble drugs in the gastro-intestinal tract using in vitro tests
Y. Arnold (2011)
10.1016/j.matpr.2020.04.109
Solid lipid nanoparticles for oral drug delivery
S. K. Basha (2020)
10.1007/s11051-012-1113-0
In vitro digestion of curcuminoid-loaded lipid nanoparticles
A. Noack (2012)
10.1016/J.ADDR.2007.10.014
Enhancing intestinal drug solubilisation using lipid-based delivery systems.
C. H. Porter (2008)
Evaluating different static in vitro digestion models and lipolysis profiles of single and double water/oil emulsions
Hebatullah Eldemnawy (2015)
ORAL LIPID BASED FORMULATION: A REVIEW
M. Patro (2010)
10.1039/C6FO00158K
Comparison of lipases for in vitro models of gastric digestion: lipolysis using two infant formulas as model substrates.
P. Sassene (2016)
10.1021/acs.molpharmaceut.5b00498
Elucidating the Molecular Interactions Occurring during Drug Precipitation of Weak Bases from Lipid-Based Formulations: A Case Study with Cinnarizine and a Long Chain Self-Nanoemulsifying Drug Delivery System.
P. Sassene (2015)
10.1208/s12248-012-9398-6
Characterising Lipid Lipolysis and Its Implication in Lipid-Based Formulation Development
N. Thomas (2012)
10.1002/jps.23205
Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations.
H. Williams (2012)
10.1002/JPS.21246
Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs.
Jean F Cuiné (2008)
iii OXIDATION OF MARINE OILS DURING IN VITRO GASTROINTESTINAL DIGESTION AND ITS EFFECTS ON STRESS IN HUMAN INTESTINAL CACO-2 CELLS
Cecilia Tullberg (2018)
10.1007/s11095-010-0362-9
Effects of Surfactants on Lipase Structure, Activity, and Inhibition
Vincent Delorme (2010)
10.1016/j.ejpb.2017.05.001
Simultaneous lipolysis/permeation in vitro model, for the estimation of bioavailability of lipid based drug delivery systems
H. A. Bibi (2017)
10.1016/S1773-2247(10)50019-4
Comparison of different in vitro tests to assess oral lipid-based formulations using a poorly soluble acidic drug
Y. Arnold (2010)
10.1016/j.ejps.2010.07.005
Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes.
Anne Christiansen (2010)
10.1007/s11095-013-0999-2
Insights into Drug Precipitation Kinetics during In Vitro Digestion of a Lipid-Based Drug Delivery System Using In-Line Raman Spectroscopy and Mathematical Modeling
Cordula Stillhart (2013)
10.1016/j.chemphyslip.2017.02.005
IR spectroscopy analysis of pancreatic lipase-related protein 2 interaction with phospholipids: 1. Discriminative recognition of mixed micelles versus liposomes.
E. Mateos-Diaz (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar